KR20150003798A - Ptp1b 연관 질병의 치료용 아미노스테로이드 - Google Patents

Ptp1b 연관 질병의 치료용 아미노스테로이드 Download PDF

Info

Publication number
KR20150003798A
KR20150003798A KR1020147031485A KR20147031485A KR20150003798A KR 20150003798 A KR20150003798 A KR 20150003798A KR 1020147031485 A KR1020147031485 A KR 1020147031485A KR 20147031485 A KR20147031485 A KR 20147031485A KR 20150003798 A KR20150003798 A KR 20150003798A
Authority
KR
South Korea
Prior art keywords
compound
ptp1b
pharmaceutically acceptable
emi
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020147031485A
Other languages
English (en)
Korean (ko)
Inventor
마이클 맥클래인
이네즈 뤼츠-화이트
더블유. 리 말로이
헨리 알. 울프
Original Assignee
오에이치알 파마서티컬, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오에이치알 파마서티컬, 인코포레이티드 filed Critical 오에이치알 파마서티컬, 인코포레이티드
Publication of KR20150003798A publication Critical patent/KR20150003798A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020147031485A 2012-04-20 2013-04-19 Ptp1b 연관 질병의 치료용 아미노스테로이드 Ceased KR20150003798A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261636252P 2012-04-20 2012-04-20
US61/636,252 2012-04-20
PCT/US2013/037330 WO2013158970A2 (en) 2012-04-20 2013-04-19 Aminosteroids for the treatment of a ptp1b associated disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020167019758A Division KR101963312B1 (ko) 2012-04-20 2013-04-19 Ptp1b 연관 질병의 치료용 아미노스테로이드

Publications (1)

Publication Number Publication Date
KR20150003798A true KR20150003798A (ko) 2015-01-09

Family

ID=48325893

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020147031485A Ceased KR20150003798A (ko) 2012-04-20 2013-04-19 Ptp1b 연관 질병의 치료용 아미노스테로이드
KR1020197008179A Active KR102057812B1 (ko) 2012-04-20 2013-04-19 Ptp1b 연관 질병의 치료용 아미노스테로이드
KR1020167019758A Expired - Fee Related KR101963312B1 (ko) 2012-04-20 2013-04-19 Ptp1b 연관 질병의 치료용 아미노스테로이드

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020197008179A Active KR102057812B1 (ko) 2012-04-20 2013-04-19 Ptp1b 연관 질병의 치료용 아미노스테로이드
KR1020167019758A Expired - Fee Related KR101963312B1 (ko) 2012-04-20 2013-04-19 Ptp1b 연관 질병의 치료용 아미노스테로이드

Country Status (15)

Country Link
US (6) US9546194B2 (enExample)
EP (2) EP3556765B1 (enExample)
JP (4) JP6165843B2 (enExample)
KR (3) KR20150003798A (enExample)
AU (3) AU2013249111B2 (enExample)
CA (1) CA2870671C (enExample)
DK (1) DK2838907T3 (enExample)
ES (1) ES2736310T3 (enExample)
HR (1) HRP20191348T1 (enExample)
HU (1) HUE044769T2 (enExample)
MX (2) MX367255B (enExample)
PL (1) PL2838907T3 (enExample)
PT (1) PT2838907T (enExample)
TR (1) TR201911039T4 (enExample)
WO (1) WO2013158970A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2838907T (pt) * 2012-04-20 2019-08-05 Ohr Pharmaceutical Inc Aminoesteróides para o tratamento de uma doença associada a ptp1b
US10040817B2 (en) 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
GB201700567D0 (en) 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
WO2019050903A1 (en) * 2017-09-08 2019-03-14 Enterin Laboratories, Inc. METHODS OF TREATING SLEEP DISORDERS, SLEEP DISTURBANCES AND ASSOCIATED SYMPTOMS USING AMINOSTEROL COMPOSITIONS
CN107802626B (zh) * 2017-10-11 2020-01-21 南昌大学 降血糖组合物及其制备方法、用途
CA3081815A1 (en) 2017-11-06 2019-05-09 Cold Spring Harbor Laboratory Method and compositions for forming a copper-containing complex and uses thereof
US20190298740A1 (en) * 2018-03-27 2019-10-03 Enterin, Inc. Methods and compositions for treating hallucinations and conditions related to the same
CN112867728B (zh) * 2018-07-20 2024-04-05 冷泉港实验室 与铜螯合的(吡啶基亚甲基)丁二胺衍生物
US20220372066A1 (en) * 2019-08-02 2022-11-24 Enterin, Inc. Human squalamine derivatives (ent-06), related compositions comprising the same, and method of using the same
EP4007764A4 (en) * 2019-08-02 2023-08-09 Enterin, Inc. HUMAN ENT-03 AMINOSTEROL COMPOUNDS, RELATED COMPOSITIONS COMPRISING THEM, AND METHODS OF USE THEREOF
WO2023230593A1 (en) 2022-05-27 2023-11-30 Cold Spring Harbor Laboratory Ptp1b inhibitors for treating lung injury

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2403683A (en) * 1942-04-25 1946-07-09 Relchstein Tadeus Compounds of the cyclopentanopolyhydrophenanthrene series and process of making same
US3636210A (en) * 1968-02-02 1972-01-18 Merck & Co Inc Cholanic acid and cholenic acid compositions and method of treatment
IT1255450B (it) * 1992-06-30 1995-10-31 Montefarmaco Spa Uso di acidi biliari come agenti antivirali
WO1994019366A1 (en) * 1993-02-26 1994-09-01 Magainin Pharmaceuticals Inc. Chemical synthesis of squalamine
WO1994020520A1 (en) 1993-03-10 1994-09-15 Magainin Pharmaceuticals Inc. Steroid derivatives, pharmaceutical compositions containing them, and their use as antibiotics or disinfectants
US5856535A (en) 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
CA2223910C (en) 1995-06-07 2008-09-16 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (nhe), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the nhe-inhibitory efficacy of compounds
US7410959B1 (en) * 2000-07-13 2008-08-12 Genaera Corporation Therapeutic uses for aminosterol compounds
DE60023923D1 (de) 1999-09-10 2005-12-15 Novo Nordisk As Modulatoren der protein tyrosin phosphatase (ptpases)
EP1214060A2 (en) 1999-09-10 2002-06-19 Novo Nordisk A/S Method of inhibiting protein tyrosine phosphatase 1b and/or t-cell protein tyrosine phosphatase and/or other ptpases with an asp residue at position 48
ATE329920T1 (de) 1999-09-10 2006-07-15 Novo Nordisk As Modulatoren der protein tyrosin phosphatase (ptpases)
CA2393135C (en) * 1999-12-09 2009-06-23 Genaera Corporation Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
DE60327946D1 (de) * 2002-12-24 2009-07-23 Univ British Columbia Angiogen-wirkende trisulfat steroide und deren verwendung
JP2006165843A (ja) * 2004-12-06 2006-06-22 Matsushita Electric Ind Co Ltd 画像処理装置
US20080058300A1 (en) * 2006-04-21 2008-03-06 Mclane Michael Induction of weight loss and the selective inhibition of PTP1B
CA2697744C (en) * 2007-09-06 2016-06-14 Genaera Corporation A method for treating diabetes
KR101260221B1 (ko) * 2011-12-01 2013-05-06 주식회사 엘지화학 마스크
PT2838907T (pt) 2012-04-20 2019-08-05 Ohr Pharmaceutical Inc Aminoesteróides para o tratamento de uma doença associada a ptp1b

Also Published As

Publication number Publication date
AU2013249111B2 (en) 2018-08-09
US20200270300A1 (en) 2020-08-27
DK2838907T3 (da) 2019-08-05
AU2018256561B2 (en) 2020-03-05
WO2013158970A3 (en) 2013-12-12
EP3556765A1 (en) 2019-10-23
PT2838907T (pt) 2019-08-05
AU2020203736A1 (en) 2020-06-25
PL2838907T3 (pl) 2019-12-31
CA2870671C (en) 2020-05-12
US20190202858A1 (en) 2019-07-04
US10556923B2 (en) 2020-02-11
MX2019009539A (es) 2019-09-26
AU2018256561A1 (en) 2018-11-22
WO2013158970A2 (en) 2013-10-24
US20230203088A1 (en) 2023-06-29
KR102057812B1 (ko) 2019-12-19
JP2015514781A (ja) 2015-05-21
MX367255B (es) 2019-08-12
HRP20191348T1 (hr) 2019-10-18
ES2736310T3 (es) 2019-12-27
KR101963312B1 (ko) 2019-03-28
AU2013249111A1 (en) 2014-11-06
JP2017178951A (ja) 2017-10-05
KR20160091435A (ko) 2016-08-02
JP2021073250A (ja) 2021-05-13
US11434257B2 (en) 2022-09-06
EP2838907B1 (en) 2019-05-22
TR201911039T4 (tr) 2019-08-21
JP6165843B2 (ja) 2017-07-19
US9546194B2 (en) 2017-01-17
EP2838907A2 (en) 2015-02-25
JP2019059781A (ja) 2019-04-18
US20150099727A1 (en) 2015-04-09
US20170129914A1 (en) 2017-05-11
AU2020203736B2 (en) 2021-12-02
MX2014012619A (es) 2015-01-15
US20250002525A1 (en) 2025-01-02
EP3556765B1 (en) 2022-02-23
KR20190034685A (ko) 2019-04-02
JP6457010B2 (ja) 2019-01-23
CA2870671A1 (en) 2013-10-24
HUE044769T2 (hu) 2019-11-28
HK1205516A1 (en) 2015-12-18

Similar Documents

Publication Publication Date Title
KR101963312B1 (ko) Ptp1b 연관 질병의 치료용 아미노스테로이드
EP2188299B1 (en) Compounds for treating diabetes
HK40016305B (en) Aminosteroids for the treatment of a ptp1b associated disease
HK40016305A (en) Aminosteroids for the treatment of a ptp1b associated disease
HK1205516B (en) Aminosteroids for the treatment of a ptp1b associated disease
WO2009091609A1 (en) A method for treating rapamycin induced diabetes-like syndrome using trodusquemine

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141110

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150210

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20151120

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20160621

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20151120

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20160720